Heart disease, according to the Centers for Disease Control and Prevention (CDC), is the leading cause of death for both men and women. With so many Americans succumbing to the disease every year it is not surprising that a significant number of biopharmaceutical companies are concentrating their efforts on developing new therapies targeting various cardiovascular disorders. A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) has identified 215 potential therapies currently in the pipeline indicated for heart disease and stroke.